AU2017339417C1 - Novel Jak1 selective inhibitors and uses thereof - Google Patents

Novel Jak1 selective inhibitors and uses thereof Download PDF

Info

Publication number
AU2017339417C1
AU2017339417C1 AU2017339417A AU2017339417A AU2017339417C1 AU 2017339417 C1 AU2017339417 C1 AU 2017339417C1 AU 2017339417 A AU2017339417 A AU 2017339417A AU 2017339417 A AU2017339417 A AU 2017339417A AU 2017339417 C1 AU2017339417 C1 AU 2017339417C1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
polymorph
solvate
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017339417A
Other languages
English (en)
Other versions
AU2017339417A1 (en
AU2017339417B2 (en
Inventor
Congxin Liang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Highlightll Pharmaceutical Co Ltd
Original Assignee
Hangzhou Highlightll Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Highlightll Pharmaceutical Co Ltd filed Critical Hangzhou Highlightll Pharmaceutical Co Ltd
Publication of AU2017339417A1 publication Critical patent/AU2017339417A1/en
Assigned to Highlightll Pharmaceutical (Hainan) Co., Ltd reassignment Highlightll Pharmaceutical (Hainan) Co., Ltd Request for Assignment Assignors: TLL Pharmaceutical, LLC
Application granted granted Critical
Publication of AU2017339417B2 publication Critical patent/AU2017339417B2/en
Priority to AU2022201058A priority Critical patent/AU2022201058B2/en
Priority to AU2022201061A priority patent/AU2022201061B2/en
Assigned to Hangzhou Highlightll Pharmaceutical Co., Ltd. reassignment Hangzhou Highlightll Pharmaceutical Co., Ltd. Request for Assignment Assignors: Highlightll Pharmaceutical (Hainan) Co., Ltd
Publication of AU2017339417C1 publication Critical patent/AU2017339417C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AU2017339417A 2016-10-03 2017-09-30 Novel Jak1 selective inhibitors and uses thereof Active AU2017339417C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022201058A AU2022201058B2 (en) 2016-10-03 2022-02-17 Novel Jak1 selective inhibitors and uses thereof
AU2022201061A AU2022201061B2 (en) 2016-10-03 2022-02-17 Novel Jak1 selective inhibitors and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662403660P 2016-10-03 2016-10-03
US62/403,660 2016-10-03
PCT/US2017/054668 WO2018067422A1 (en) 2016-10-03 2017-09-30 Novel jak1 selective inhibitors and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2022201058A Division AU2022201058B2 (en) 2016-10-03 2022-02-17 Novel Jak1 selective inhibitors and uses thereof
AU2022201061A Division AU2022201061B2 (en) 2016-10-03 2022-02-17 Novel Jak1 selective inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
AU2017339417A1 AU2017339417A1 (en) 2019-03-28
AU2017339417B2 AU2017339417B2 (en) 2021-11-18
AU2017339417C1 true AU2017339417C1 (en) 2022-06-02

Family

ID=61831161

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017339417A Active AU2017339417C1 (en) 2016-10-03 2017-09-30 Novel Jak1 selective inhibitors and uses thereof
AU2022201058A Active AU2022201058B2 (en) 2016-10-03 2022-02-17 Novel Jak1 selective inhibitors and uses thereof
AU2022201061A Active AU2022201061B2 (en) 2016-10-03 2022-02-17 Novel Jak1 selective inhibitors and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022201058A Active AU2022201058B2 (en) 2016-10-03 2022-02-17 Novel Jak1 selective inhibitors and uses thereof
AU2022201061A Active AU2022201061B2 (en) 2016-10-03 2022-02-17 Novel Jak1 selective inhibitors and uses thereof

Country Status (19)

Country Link
US (3) US10738060B2 (https=)
EP (1) EP3509591B1 (https=)
JP (1) JP7089141B2 (https=)
KR (1) KR102399848B1 (https=)
CN (2) CN113214278B (https=)
AU (3) AU2017339417C1 (https=)
DK (1) DK3509591T3 (https=)
EA (1) EA201990523A1 (https=)
ES (1) ES2901216T3 (https=)
HK (1) HK1253040A1 (https=)
HR (1) HRP20211965T1 (https=)
HU (1) HUE058120T2 (https=)
IL (3) IL265358B (https=)
MX (1) MX390005B (https=)
NZ (1) NZ751284A (https=)
PL (1) PL3509591T3 (https=)
PT (1) PT3509591T (https=)
RS (1) RS62695B1 (https=)
WO (1) WO2018067422A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX390005B (es) * 2016-10-03 2025-03-20 Hangzhou Highlightll Pharmaceutical Co Ltd Inhibidores selectivos de jak1 novedosos y usos de los mismos.
LT3568396T (lt) * 2017-01-11 2021-02-10 Leo Pharma A/S Nauji amino-imidazopiridino dariniai, kaip janus kinazės inhibitoriai ir jų farmacinis panaudojimas
CA3117969A1 (en) 2018-10-31 2020-05-07 Incyte Corporation Combination therapy for treatment of hematological diseases
WO2020181034A1 (en) * 2019-03-05 2020-09-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
BR112021024533A2 (pt) * 2019-06-06 2022-01-18 Highlightll Pharmaceutical Hainan Co Ltd Método de síntese de composto de furoimidazopiridina, forma cristalina de composto de furoimidazopiridina, e forma cristalina de sal do mesmo
WO2020244349A1 (zh) * 2019-06-06 2020-12-10 广州高瓴制药有限公司 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物
EP4153566A1 (en) 2020-05-19 2023-03-29 Bayer CropScience Aktiengesellschaft Azabicyclic(thio)amides as fungicidal compounds
CA3186659A1 (en) 2020-06-10 2021-12-16 Bayer Aktiengesellschaft Azabicyclyl-substituted heterocycles as fungicides
US20240307396A1 (en) * 2021-06-07 2024-09-19 The Regents Of The University Of California Compositions and methods for treating celiac disease
AU2022342095A1 (en) * 2021-09-13 2024-06-27 Hangzhou Highlightll Pharmaceutical Co., Ltd Methods of treating cns disorders
CN114213424B (zh) * 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法
WO2025224600A1 (en) * 2024-04-21 2025-10-30 Biohaven Therapeutics Ltd. Treatment of alpha-synucleinopathies and neuroprotection
WO2025248468A1 (en) 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria)
WO2026002028A1 (zh) * 2024-06-26 2026-01-02 杭州多域生物技术有限公司 稠杂芳环类化合物、其药物组合物及其应用
WO2026032213A1 (zh) * 2024-08-08 2026-02-12 普罗思特(南京)生物科技有限公司 取代的三环衍生物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1104764A1 (en) * 1998-08-12 2001-06-06 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridine derivatives
WO2014071031A1 (en) * 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983092A (en) 1975-01-20 1976-09-28 Ciba-Geigy Corporation Phenylindane diamine mixture and epoxy resin therewith
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
DE69924735T2 (de) 1998-07-28 2006-01-19 Tanabe Seiyaku Co., Ltd. Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6800663B2 (en) 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
JP2007526324A (ja) 2004-03-02 2007-09-13 スミスクライン・ビーチャム・コーポレイション Ａｋｔ活性のある阻害剤
CN101282761A (zh) * 2005-08-04 2008-10-08 西特里斯药业公司 作为sirtuin调节剂的苯并咪唑衍生物
US7790288B2 (en) 2005-08-11 2010-09-07 3M Innovative Properties Company Interpenetrating polymer network as coating for metal substrate and method therefor
WO2007039146A1 (en) 2005-09-23 2007-04-12 Smithkline Beecham Corporation 4-carboxy pyrazole derivatives as anti-viral agents
US7879968B2 (en) 2006-10-17 2011-02-01 Taylor Made Golf Company, Inc. Polymer compositions and golf balls with reduced yellowing
US20100280151A1 (en) 2009-05-04 2010-11-04 Toray Industries, Inc. Toughened fiber reinforced polymer composite with core-shell particles
JP2013505965A (ja) * 2009-09-29 2013-02-21 エックスカバリー ホールディング カンパニー エルエルシー Ｐｉ３ｋ（デルタ）選択的阻害剤
WO2011138657A1 (en) 2010-05-04 2011-11-10 Glenmark Pharmaceuticals S.A. Aryl substituted olefinic compounds as pde10a inhibitors
WO2012022045A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
RU2013120966A (ru) 2010-10-08 2014-11-20 Эббви Инк. ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
AU2012295802B2 (en) 2011-08-12 2017-03-30 Nissan Chemical Industries, Ltd. Tricyclic heterocyclic compounds and JAK inhibitors
WO2013051672A1 (ja) 2011-10-04 2013-04-11 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とする医薬品
CN103450125B (zh) 2013-07-18 2016-01-13 嘉兴中科化学有限公司 一种5-取代苯丙呋喃-2-羧酸及其衍生物的合成方法
AU2014339897A1 (en) 2013-10-24 2016-04-21 Abbvie Inc. JAK1 selective inhibitor and uses thereof
MA39987A (fr) 2014-04-30 2017-03-08 Incyte Corp Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
EP2940022B1 (en) 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CN105418620B (zh) 2014-09-23 2018-05-04 天津药明康德新药开发有限公司 一种4-(叔丁氧羰基)八氢呋喃并[3,2-b]吡啶-6-羧酸的合成方法
WO2016100349A2 (en) 2014-12-16 2016-06-23 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
CN106432232A (zh) 2016-09-18 2017-02-22 苏州汉德创宏生化科技有限公司 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法
MX390005B (es) 2016-10-03 2025-03-20 Hangzhou Highlightll Pharmaceutical Co Ltd Inhibidores selectivos de jak1 novedosos y usos de los mismos.
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
CN107216334A (zh) 2017-06-29 2017-09-29 上海吉尔多肽有限公司 一种6‑氯呋喃[3,2‑b]吡啶的合成方法
WO2020244349A1 (zh) 2019-06-06 2020-12-10 广州高瓴制药有限公司 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物
CN118619944A (zh) 2019-06-06 2024-09-10 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
BR112021024533A2 (pt) 2019-06-06 2022-01-18 Highlightll Pharmaceutical Hainan Co Ltd Método de síntese de composto de furoimidazopiridina, forma cristalina de composto de furoimidazopiridina, e forma cristalina de sal do mesmo
CN114213424B (zh) 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1104764A1 (en) * 1998-08-12 2001-06-06 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridine derivatives
WO2014071031A1 (en) * 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors

Also Published As

Publication number Publication date
US10738060B2 (en) 2020-08-11
IL291267A (en) 2022-05-01
AU2017339417A1 (en) 2019-03-28
CN108366994A (zh) 2018-08-03
BR112019005969A2 (pt) 2019-06-18
PL3509591T3 (pl) 2022-01-31
IL291267B1 (en) 2023-01-01
HRP20211965T1 (hr) 2022-03-18
MX390005B (es) 2025-03-20
AU2022201061A1 (en) 2022-03-10
PT3509591T (pt) 2021-12-27
AU2022201061B2 (en) 2023-03-16
WO2018067422A1 (en) 2018-04-12
KR102399848B1 (ko) 2022-05-19
CN113214278A (zh) 2021-08-06
KR20190057069A (ko) 2019-05-27
JP2019537559A (ja) 2019-12-26
IL291265B1 (en) 2023-01-01
DK3509591T3 (da) 2021-12-20
CA3039178A1 (en) 2018-04-12
EP3509591A1 (en) 2019-07-17
IL291267B2 (en) 2023-05-01
AU2022201058B2 (en) 2023-03-16
IL291265B2 (en) 2023-05-01
JP7089141B2 (ja) 2022-06-22
RS62695B1 (sr) 2022-01-31
CN108366994B (zh) 2021-10-01
USRE50799E1 (en) 2026-02-17
IL265358B (en) 2022-04-01
US20190256523A1 (en) 2019-08-22
EP3509591B1 (en) 2021-11-17
EP3509591A4 (en) 2020-03-25
AU2022201058A1 (en) 2022-03-10
EA201990523A1 (ru) 2019-10-31
IL291265A (en) 2022-05-01
HK1253040A1 (zh) 2019-06-06
AU2017339417B2 (en) 2021-11-18
MX2019003649A (es) 2019-08-14
CN113214278B (zh) 2022-10-28
USRE49834E1 (en) 2024-02-13
HUE058120T2 (hu) 2022-07-28
NZ751284A (en) 2022-09-30
ES2901216T3 (es) 2022-03-21
IL265358A (en) 2019-05-30

Similar Documents

Publication Publication Date Title
AU2022201061B2 (en) Novel Jak1 selective inhibitors and uses thereof
EP4083038B1 (en) Pyridazinyl thiazolecarboxamide compound
CN112368278B (zh) Rip1抑制性化合物以及制备和使用其的方法
EP3473626B1 (en) Pyrrolopyrimidine crystal for preparing jak inhibitor
JP6389511B2 (ja) 癌を治療するための、ｎｉｋ阻害剤としての３−（２−アミノピリミジン−４−イル）−５−（３−ヒドロキシプロピニル）−１ｈ−ピロロ［２，３−ｃ］ピリジン誘導体
CN115279763A (zh) Rip1抑制化合物以及制备和使用所述化合物的方法
EP3568396A1 (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
WO2019070167A1 (ru) Ингибиторы рецептора эпидермального фактора роста
CA3039178C (en) Novel jak1 selective inhibitors and uses thereof
HK40004735B (en) Novel jak1 selective inhibitors and uses thereof
HK40047523B (en) Novel jak1 selective inhibitors and uses thereof
HK40047523A (en) Novel jak1 selective inhibitors and uses thereof
BR112019005969B1 (pt) Inibidores seletivos de jak1 e usos dos mesmos
EA040948B1 (ru) Селективные ингибиторы jak1 и их применение
HK40079587A (en) Crystal form of pyridazine derivative free base, and preparation method therefor and use thereof
HK40082783A (en) Rip1 inhibitory compounds and methods for making and using the same
HK1142067A (en) 9-(pyraxzol-3-yl)-9h-purine-2-amine and 3-(pyrazol-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: HIGHLIGHTLL PHARMACEUTICAL (HAINAN) CO., LTD

Free format text: FORMER APPLICANT(S): TLL PHARMACEUTICAL, LLC

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 17 FEB 2022

PC1 Assignment before grant (sect. 113)

Owner name: HANGZHOU HIGHLIGHTLL PHARMACEUTICAL CO., LTD.

Free format text: FORMER APPLICANT(S): HIGHLIGHTLL PHARMACEUTICAL (HAINAN) CO., LTD

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 17 FEB 2022

FGA Letters patent sealed or granted (standard patent)